$17.6 Billion is the total value of Baker Brothers Advisors's 117 reported holdings in Q2 2022. The portfolio turnover from Q1 2022 to Q2 2022 was 9.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SGEN | Seagen Inc. | $8,300,656,000 | +22.8% | 46,912,266 | 0.0% | 47.09% | +21.3% | |
| INCY | Buy | Incyte Corporation | $2,746,628,000 | -4.3% | 36,154,117 | +0.0% | 15.58% | -5.6% |
| BGNE | BeiGene, Ltd.sponsored adr | $1,888,611,000 | -14.2% | 11,668,897 | 0.0% | 10.71% | -15.3% | |
| BMRN | BioMarin Pharmaceutical Inc. | $631,510,000 | +7.5% | 7,620,494 | 0.0% | 3.58% | +6.1% | |
| ACAD | Buy | ACADIA Pharmaceuticals Inc. | $590,702,000 | -41.8% | 41,923,486 | +0.0% | 3.35% | -42.6% |
| ASND | Buy | Ascendis Pharma A/Ssponsored adr | $451,103,000 | -15.4% | 4,852,655 | +6.8% | 2.56% | -16.5% |
| ARGX | argenx SEsponsored adr | $424,178,000 | +20.2% | 1,119,557 | 0.0% | 2.41% | +18.6% | |
| BCRX | BioCryst Pharmaceuticals, Inc. | $134,480,000 | -34.9% | 12,710,818 | 0.0% | 0.76% | -35.8% | |
| KOD | Buy | Kodiak Sciences Inc. | $132,252,000 | +7.5% | 17,310,490 | +8.7% | 0.75% | +6.1% |
| GBT | Buy | Global Blood Therapeutics, Inc. | $119,253,000 | +3.9% | 3,732,502 | +12.6% | 0.68% | +2.6% |
| ABCL | AbCellera Biologics Inc. | $111,294,000 | +9.2% | 10,450,180 | 0.0% | 0.63% | +7.9% | |
| MDGL | Madrigal Pharmaceuticals, Inc. | $107,314,000 | -27.0% | 1,499,213 | 0.0% | 0.61% | -27.9% | |
| MRTX | Mirati Therapeutics, Inc. | $94,639,000 | -18.4% | 1,409,784 | 0.0% | 0.54% | -19.4% | |
| IMCR | Immunocore Holdings plcads | $94,048,000 | +24.8% | 2,520,730 | 0.0% | 0.53% | +23.3% | |
| HZNP | Buy | Horizon Therapeutics Public Ltd Co | $91,605,000 | -3.1% | 1,148,504 | +27.8% | 0.52% | -4.2% |
| CERS | Buy | Cerus Corporation | $84,997,000 | +12.9% | 16,067,558 | +17.2% | 0.48% | +11.3% |
| TVTX | Travere Therapeutics, Inc. | $79,959,000 | -6.0% | 3,300,009 | 0.0% | 0.45% | -7.2% | |
| REPL | Buy | Replimune Group, Inc. | $62,772,000 | +129.4% | 3,591,081 | +122.8% | 0.36% | +126.8% |
| Buy | Entrada Therapeutics, Inc. | $59,266,000 | +34.2% | 4,865,819 | +3.4% | 0.34% | +32.3% | |
| IGMS | IGM Biosciences, Inc. | $56,905,000 | -32.5% | 3,156,102 | 0.0% | 0.32% | -33.4% | |
| KYMR | Buy | Kymera Therapeutics, Inc. | $56,704,000 | -43.8% | 2,879,825 | +20.8% | 0.32% | -44.5% |
| KRYS | Krystal Biotech, Inc. | $53,036,000 | -1.3% | 807,735 | 0.0% | 0.30% | -2.6% | |
| PRLD | Prelude Therapeutics Inc. | $52,846,000 | -24.3% | 10,123,824 | 0.0% | 0.30% | -25.2% | |
| NRIX | Buy | Nurix Therapeutics, Inc. | $49,187,000 | +43.1% | 3,882,125 | +58.2% | 0.28% | +40.9% |
| LEGN | Sell | Legend Biotech Corporationsponsored ads | $47,116,000 | -35.5% | 856,658 | -57.4% | 0.27% | -36.3% |
| ALKS | Alkermes plc | $44,685,000 | +13.2% | 1,500,000 | 0.0% | 0.25% | +11.9% | |
| CCXI | Buy | ChemoCentryx, Inc. | $44,422,000 | +93.3% | 1,792,657 | +95.5% | 0.25% | +90.9% |
| KDNY | Buy | Chinook Therapeutics, Inc. | $44,321,000 | +16.1% | 2,534,102 | +8.6% | 0.25% | +14.6% |
| INSM | Insmed Incorporated | $42,516,000 | -16.1% | 2,156,001 | 0.0% | 0.24% | -17.2% | |
| IMTX | Immatics N.V. | $38,531,000 | +9.0% | 4,423,731 | 0.0% | 0.22% | +7.9% | |
| DBVT | DBV Technologies S.A.sponsored adr | $37,266,000 | +60.4% | 14,614,264 | 0.0% | 0.21% | +57.5% | |
| Sarepta Therapeutics, Inc.dbcv 1.5% 11/15/2024 | $36,577,000 | -4.6% | 29,174,000 | 0.0% | 0.21% | -5.5% | ||
| Insmed Incorporatednote 0.75% 6/1/2028 | $33,278,000 | -13.8% | 40,000,000 | 0.0% | 0.19% | -14.9% | ||
| AVTE | Aerovate Therapeutics, Inc. | $32,354,000 | -14.7% | 2,070,010 | 0.0% | 0.18% | -15.6% | |
| AMRN | Amarin Corporation plcsponsored adr | $31,543,000 | -54.7% | 21,169,805 | 0.0% | 0.18% | -55.2% | |
| VSTM | Verastem, Inc. | $31,307,000 | -17.7% | 26,988,898 | 0.0% | 0.18% | -18.7% | |
| RARE | Buy | Ultragenyx Pharmaceutical Inc. | $28,098,000 | -12.9% | 470,974 | +6.0% | 0.16% | -14.1% |
| KNSA | Kiniksa Pharmaceuticals, Ltd. | $27,128,000 | -2.5% | 2,799,577 | 0.0% | 0.15% | -3.8% | |
| 2seventy bio, Inc. | $27,228,000 | -22.6% | 2,062,744 | 0.0% | 0.15% | -23.8% | ||
| BMEA | Buy | Biomea Fusion, Inc. | $25,213,000 | +264.4% | 2,104,559 | +35.7% | 0.14% | +257.5% |
| ALT | Buy | Altimmune, Inc. | $24,282,000 | +271.9% | 2,075,403 | +93.6% | 0.14% | +263.2% |
| NVTA | Invitae Corporation | $24,091,000 | -69.4% | 9,873,488 | 0.0% | 0.14% | -69.7% | |
| PACB | Pacific Biosciences of California, Inc. | $24,067,000 | -51.4% | 5,444,963 | 0.0% | 0.14% | -51.9% | |
| XENE | Xenon Pharmaceuticals Inc. | $22,865,000 | -0.5% | 751,639 | 0.0% | 0.13% | -1.5% | |
| HRTX | Heron Therapeutics, Inc. | $22,687,000 | -51.2% | 8,131,678 | 0.0% | 0.13% | -51.7% | |
| MRUS | Sell | Merus N.V. | $22,536,000 | -58.2% | 995,397 | -51.1% | 0.13% | -58.7% |
| VERV | Verve Therapeutics, Inc. | $21,645,000 | -33.0% | 1,416,530 | 0.0% | 0.12% | -33.9% | |
| DSGN | Design Therapeutics, Inc. | $20,113,000 | -13.3% | 1,436,636 | 0.0% | 0.11% | -14.3% | |
| AFMD | Buy | Affimed N.V. | $18,273,000 | -18.9% | 6,596,830 | +28.0% | 0.10% | -19.4% |
| TIL | Instil Bio, Inc. | $17,989,000 | -57.0% | 3,893,700 | 0.0% | 0.10% | -57.7% | |
| OTIC | Buy | Otonomy, Inc. | $17,498,000 | -7.1% | 8,412,634 | +7.2% | 0.10% | -8.3% |
| DNLI | Buy | Denali Therapeutics Inc. | $17,327,000 | +506.9% | 588,738 | +563.5% | 0.10% | +512.5% |
| RYTM | Rhythm Pharmaceuticals, Inc. | $17,119,000 | -64.0% | 4,125,062 | 0.0% | 0.10% | -64.5% | |
| OPT | Opthea Limitedsponsored ads | $16,986,000 | -8.1% | 2,696,191 | 0.0% | 0.10% | -9.4% | |
| ADAP | Adaptimmune Therapeutics plcsponsored adr | $16,712,000 | -17.5% | 9,830,877 | 0.0% | 0.10% | -18.1% | |
| CRNX | Crinetics Pharmaceuticals, Inc. | $15,433,000 | -15.0% | 827,480 | 0.0% | 0.09% | -15.4% | |
| TCDA | Sell | Tricida, Inc. | $14,550,000 | +2.2% | 1,503,090 | -13.2% | 0.08% | +1.2% |
| FMTX | Forma Therapeutics Holdings, Inc. | $13,951,000 | -25.9% | 2,024,876 | 0.0% | 0.08% | -26.9% | |
| FLGT | Fulgent Genetics, Inc. | $10,985,000 | -12.6% | 201,444 | 0.0% | 0.06% | -13.9% | |
| BLUE | bluebird bio, Inc. | $10,349,000 | -14.6% | 2,499,715 | 0.0% | 0.06% | -15.7% | |
| RLMD | Relmada Therapeutics, Inc. | $9,402,000 | -29.6% | 495,113 | 0.0% | 0.05% | -31.2% | |
| DICE Therapeutics, Inc. | $9,129,000 | -18.9% | 588,235 | 0.0% | 0.05% | -20.0% | ||
| ZYME | Zymeworks Inc. | $9,055,000 | -19.1% | 1,708,472 | 0.0% | 0.05% | -20.3% | |
| Buy | TScan Therapeutics, Inc. | $8,758,000 | +119.5% | 2,784,792 | +95.4% | 0.05% | +117.4% | |
| KRTX | Karuna Therapeutics, Inc. | $8,851,000 | -0.2% | 69,966 | 0.0% | 0.05% | -2.0% | |
| FGEN | Buy | FibroGen, Inc. | $8,614,000 | +23.2% | 815,718 | +40.2% | 0.05% | +22.5% |
| ANAB | AnaptysBio, Inc. | $8,672,000 | -17.9% | 427,179 | 0.0% | 0.05% | -19.7% | |
| Invitae Corporationnote 2.0% 9/1/2024 | $8,087,000 | -3.5% | 10,300,000 | 0.0% | 0.05% | -4.2% | ||
| CYT | Buy | Cyteir Therapeutics, Inc. | $7,904,000 | +158.0% | 2,643,640 | +225.3% | 0.04% | +150.0% |
| Surrozen, Inc. | $7,500,000 | -0.3% | 2,500,000 | 0.0% | 0.04% | 0.0% | ||
| RETA | Reata Pharmaceuticals, Inc.cl a | $6,807,000 | -7.2% | 223,976 | 0.0% | 0.04% | -7.1% | |
| ACHL | Achilles Therapeutics plcsponsored ads | $6,530,000 | -14.3% | 2,591,366 | 0.0% | 0.04% | -15.9% | |
| CBAY | CymaBay Therapeutics, Inc. | $6,403,000 | -5.1% | 2,170,464 | 0.0% | 0.04% | -7.7% | |
| BCEL | Atreca, Inc. | $6,324,000 | -43.5% | 3,532,760 | 0.0% | 0.04% | -43.8% | |
| TLIS | Talis Biomedical Corporation | $6,191,000 | -42.4% | 7,624,835 | 0.0% | 0.04% | -43.5% | |
| HRMY | Harmony Biosciences Holdings, Inc. | $6,028,000 | +0.2% | 123,600 | 0.0% | 0.03% | -2.9% | |
| ATRA | New | Atara Biotherapeutics, Inc. | $5,797,000 | – | 744,186 | +100.0% | 0.03% | – |
| VOR | New | Vor Biopharma Inc. | $5,660,000 | – | 1,138,768 | +100.0% | 0.03% | – |
| CNTA | Centessa Pharmaceuticals plcsponsored ads | $5,490,000 | -45.7% | 1,127,273 | 0.0% | 0.03% | -46.6% | |
| NKTX | New | Nkarta, Inc. | $4,928,000 | – | 400,000 | +100.0% | 0.03% | – |
| VERA | Vera Therapeutics, Inc.cl a | $4,537,000 | -42.1% | 333,333 | 0.0% | 0.03% | -42.2% | |
| RVMD | Revolution Medicines, Inc. | $4,331,000 | -23.6% | 222,222 | 0.0% | 0.02% | -24.2% | |
| EWTX | Edgewise Therapeutics, Inc. | $3,980,000 | -17.9% | 500,000 | 0.0% | 0.02% | -17.9% | |
| HOOK | HOOKIPA Pharma Inc. | $3,913,000 | -28.5% | 2,400,481 | 0.0% | 0.02% | -29.0% | |
| NLTX | Neoleukin Therapeutics, Inc. | $3,936,000 | -45.2% | 3,821,740 | 0.0% | 0.02% | -46.3% | |
| NTRA | New | Natera, Inc. | $3,544,000 | – | 100,000 | +100.0% | 0.02% | – |
| Tango Therapeutics, Inc. | $3,398,000 | -40.2% | 750,000 | 0.0% | 0.02% | -42.4% | ||
| ITOS | iTeos Therapeutics, Inc. | $3,097,000 | -36.0% | 150,346 | 0.0% | 0.02% | -35.7% | |
| ATHA | Buy | Athira Pharma, Inc. | $3,175,000 | -70.8% | 1,040,834 | +29.1% | 0.02% | -71.4% |
| New | Evofem Biosciences, Inc. | $2,919,000 | – | 2,583,616 | +100.0% | 0.02% | – | |
| MGNX | Buy | MacroGenics, Inc. | $2,633,000 | -32.5% | 892,579 | +101.7% | 0.02% | -31.8% |
| ALEC | Alector, Inc. | $2,431,000 | -28.7% | 239,228 | 0.0% | 0.01% | -30.0% | |
| ALGS | Aligos Therapeutics, Inc. | $2,512,000 | -43.7% | 2,076,400 | 0.0% | 0.01% | -46.2% | |
| BCAB | BioAtla, Inc. | $2,351,000 | -43.0% | 825,000 | 0.0% | 0.01% | -45.8% | |
| ALLK | Allakos Inc. | $2,201,000 | -45.1% | 703,050 | 0.0% | 0.01% | -47.8% | |
| TCRR | TCR2 Therapeutics Inc. | $2,184,000 | +5.1% | 753,064 | 0.0% | 0.01% | 0.0% | |
| SNDX | Syndax Pharmaceuticals, Inc. | $2,130,000 | +10.7% | 110,729 | 0.0% | 0.01% | +9.1% | |
| AGLE | Aeglea BioTherapeutics, Inc. | $1,722,000 | -78.0% | 3,410,106 | 0.0% | 0.01% | -77.8% | |
| EPZM | Epizyme, Inc. | $1,470,000 | +27.8% | 1,000,000 | 0.0% | 0.01% | +14.3% | |
| AKRO | Akero Therapeutics, Inc. | $1,119,000 | -33.4% | 118,378 | 0.0% | 0.01% | -40.0% | |
| LIFE | Sell | aTyr Pharma, Inc. | $1,060,000 | -68.3% | 374,395 | -40.1% | 0.01% | -68.4% |
| CABA | Cabaletta Bio, Inc. | $702,000 | -47.8% | 662,063 | 0.0% | 0.00% | -50.0% | |
| LPTX | Leap Therapeutics, Inc. | $644,000 | -34.2% | 559,705 | 0.0% | 0.00% | -33.3% | |
| GTH | Genetron Holdings Limitedads | $774,000 | -22.4% | 455,306 | 0.0% | 0.00% | -33.3% | |
| NGM | Sell | NGM Biopharmaceuticals, Inc. | $709,000 | -84.1% | 55,294 | -81.1% | 0.00% | -84.6% |
| TARA | Protara Therapeutics, Inc. | $585,000 | -42.6% | 199,671 | 0.0% | 0.00% | -50.0% | |
| KZR | Sell | Kezar Life Sciences, Inc. | $512,000 | -77.9% | 61,946 | -55.7% | 0.00% | -76.9% |
| INZY | Inozyme Pharma, Inc. | $510,000 | +16.4% | 106,999 | 0.0% | 0.00% | 0.0% | |
| FHTX | Foghorn Therapeutics Inc. | $612,000 | -10.8% | 45,027 | 0.0% | 0.00% | -25.0% | |
| BNR | Burning Rock Biotech Limitedsponsored ads | $609,000 | -68.7% | 209,131 | 0.0% | 0.00% | -72.7% | |
| VINC | Vincerx Pharma, Inc. | $319,000 | -67.0% | 241,379 | 0.0% | 0.00% | -66.7% | |
| Bellicum Pharmaceuticals, Inc. | $296,000 | -45.0% | 249,123 | 0.0% | 0.00% | -33.3% | ||
| Sera Prognostics, Inc. | $331,000 | -56.7% | 201,562 | 0.0% | 0.00% | -50.0% | ||
| PASG | Passage Bio, Inc. | $276,000 | -24.0% | 117,161 | 0.0% | 0.00% | 0.0% | |
| LOGC | LogicBio Therapeutics, Inc. | $158,000 | -48.5% | 451,478 | 0.0% | 0.00% | -50.0% | |
| Surrozen, Inc.w exp 8/11/2026 | $159,000 | -23.6% | 833,333 | 0.0% | 0.00% | 0.0% | ||
| NEXI | Sell | NexImmune, Inc. | $32,000 | -97.4% | 20,000 | -93.2% | 0.00% | -100.0% |
| OYST | Exit | Oyster Point Pharma, Inc. | $0 | – | -61,424 | -100.0% | -0.00% | – |
| NVAX | Exit | Novavax, Inc. | $0 | – | -48,168 | -100.0% | -0.02% | – |
| KURA | Exit | Kura Oncology, Inc. | $0 | – | -274,458 | -100.0% | -0.02% | – |
| SRPT | Exit | Sarepta Therapeutics, Inc. | $0 | – | -123,456 | -100.0% | -0.06% | – |
| AXSM | Exit | Axsome Therapeutics, Inc. | $0 | – | -610,970 | -100.0% | -0.14% | – |
| NBIX | Exit | Neurocrine Biosciences, Inc. | $0 | – | -676,975 | -100.0% | -0.36% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-08-15
About Baker Brothers Advisors
Baker Brothers Advisors is a well-known investment management firm that specializes in the healthcare sector. The firm was founded in 2000 by brothers Julian and Felix Baker, who are both highly respected in the industry. Julian Baker is the CEO of the firm, while Felix Baker serves as a managing partner.
Baker Brothers Advisors has a reputation for investing in innovative healthcare companies that have the potential to make a significant impact on the industry. The firm has a long-term investment approach and is known for taking large positions in companies that it believes in. Some of the firm's most successful investments include companies such as Pharmacyclics, which was acquired by AbbVie for $21 billion, and Ariad Pharmaceuticals, which was acquired by Takeda for $5.2 billion.
The firm's investment strategy is led by its Chief Investment Officer, Dr. Robert Duggan, who has a background in both medicine and finance. Dr. Duggan is known for his ability to identify promising healthcare companies and for his willingness to take risks on early-stage companies.
Overall, Baker Brothers Advisors is a highly respected investment management firm that has a proven track record of success in the healthcare sector. While the firm's investment approach may not be suitable for all investors, those who are interested in the healthcare sector may want to consider Baker Brothers Advisors as a potential investment opportunity.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Incyte Corporation | 42 | Q3 2023 | 37.6% |
| ACADIA Pharmaceuticals Inc. | 42 | Q3 2023 | 10.9% |
| Biomarin Pharmaceuticals Inc. | 42 | Q3 2023 | 5.9% |
| BioCryst Pharmaceuticals, Inc. | 42 | Q3 2023 | 1.7% |
| Cerus Corporation | 42 | Q3 2023 | 0.9% |
| Insmed Incorporated | 42 | Q3 2023 | 0.4% |
| Mirati Therapeutics, Inc. | 41 | Q3 2023 | 1.8% |
| Bluebird Bio Inc. | 41 | Q3 2023 | 0.3% |
| Heron Therapeutics, Inc. | 39 | Q3 2023 | 1.5% |
| ChemoCentryx, Inc. | 37 | Q3 2022 | 0.6% |
View Baker Brothers Advisors's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Neoleukin Therapeutics, Inc. | August 17, 2023 | 9,469,838 | 20.0% |
| Mereo Biopharma Group plc | August 10, 2023 | 14,604,391 | 2.2% |
| Verastem, Inc. | August 10, 2023 | ? | ? |
| TScan Therapeutics, Inc. | June 02, 2023 | 2,793,938 | 6.5% |
| ACADIA PHARMACEUTICALS INC | May 24, 2023 | 43,084,280 | 26.5% |
| INCYTE CORP | March 15, 2023 | 36,280,967 | 16.3% |
| Seagen Inc. | March 13, 2023 | 46,985,656 | 25.1% |
| Talis Biomedical Corp | March 10, 2023 | 37,569,140 | 66.2% |
| Aeglea BioTherapeutics, Inc. | February 14, 2023 | 6,384,013 | 9.9% |
| Merus N.V. | February 14, 2023 | ? | ? |
View Baker Brothers Advisors's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 3 | 2024-04-18 |
| SC 13D | 2024-04-18 |
| 3 | 2024-04-01 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| SC 13D | 2024-04-01 |
| 4 | 2024-03-28 |
| SC 13D/A | 2024-03-28 |
| 4 | 2024-03-25 |
View Baker Brothers Advisors's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.